Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

The stock rallies as C3.ai touts enterprise AI momentum, but rising pressure from rivals puts its niche to the test.

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

The all-new LG C5 OLED TV was released in March of this year, and Amazon just dropped the 55-inch model to $1,396.99 - a new ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Investors are hopeful that C3.ai (NYSE: AI) can deliver results similar to Palantir (NASDAQ: PLTR). *Stock prices used were the afternoon prices of July 23, 2025. The video was published on July 25, ...